Semaglutide vs. Tirzepatide: Which Weight Loss Injection is Better?
If you are looking at weight loss injections in Kuwait, the choice usually comes down to two active ingredients: semaglutide and tirzepatide. Semaglutide is the medicine inside Wegovy and Ozempic. Tirzepatide is the medicine inside Mounjaro and Zepbound.
The short answer is that tirzepatide causes more weight loss—roughly 20% of your body weight compared to about 14% with standard semaglutide. But semaglutide has a proven track record for protecting the heart against strokes and heart attacks, which tirzepatide does not yet have.
Both medications are officially registered in Kuwait, available in local pharmacies, and recently saw government-mandated price cuts of 30% to 37%. Choosing between them depends on your body mass index (BMI), your medical history, and how your stomach handles the medication.
Here is exactly how these two treatments compare, based on the latest clinical data.
How they work: Single vs. Dual Action
To understand why these drugs work differently, you have to look at what they do inside your body. Both medications are synthetic peptides that mimic natural hormones your gut releases when you eat.
Semaglutide is a single-action medication. It mimics one hormone called GLP-1 (glucagon-like peptide-1). When you inject it, it tells your brain you are full, slows down how fast your stomach empties, and helps your pancreas release insulin when your blood sugar goes up. It stays in your system for about seven days, which is why you take it once a week.
Tirzepatide takes a different approach. It is a dual-action medication. It mimics GLP-1, but it also mimics a second hormone called GIP (glucose-dependent insulinotropic polypeptide).
Think of it like a twin-engine system. The GLP-1 part suppresses your appetite. The GIP part works directly on your fat cells to improve how your body handles sugar and fat. Interestingly, tirzepatide actually binds to the GLP-1 receptor about five times weaker than natural GLP-1 does [willard_jci_2020]. But because it strongly activates the GIP receptor at the same time, the combined effect produces a much stronger weight loss result.
The Head-to-Head Results: SURMOUNT-5
For a long time, doctors had to guess exactly how much better tirzepatide was than semaglutide by comparing different studies. That changed in early 2025 with the publication of the SURMOUNT-5 trial [surmount5_nejm_2025].
This was a massive study where researchers put 751 adults with obesity on either the highest tolerated dose of tirzepatide (10 or 15 mg) or the highest tolerated dose of semaglutide (1.7 or 2.4 mg) for 72 weeks.
The results were incredibly clear.
People taking tirzepatide lost an average of 20.2% of their body weight. Those taking semaglutide lost 13.7%. In plain numbers, the tirzepatide group lost about 22.8 kg (50 lbs), while the semaglutide group lost 15.0 kg (33 lbs).
Tirzepatide also helped more people hit major milestones. Nearly 20 out of 100 people on tirzepatide lost at least 30% of their body weight. Only about 7 out of 100 people on semaglutide reached that same mark [surmount5_nejm_2025].
The Heart Health Difference
If tirzepatide causes more weight loss, you might wonder why anyone would choose semaglutide. The answer comes down to your heart.
Semaglutide has a massive clinical advantage when it comes to cardiovascular health. In a landmark study called the SELECT trial, researchers followed over 17,000 people with heart disease and obesity for several years. They found that semaglutide reduced the risk of major heart events—like heart attacks and strokes—by 20% [select_trial_2023].
Because of this data, semaglutide (Wegovy) is officially approved to reduce cardiovascular risk. Tirzepatide does not have this approval yet.
In practice, if you are a patient in Kuwait with a history of heart problems, high blood pressure, or previous strokes, your doctor will likely recommend semaglutide first. The proven heart protection often outweighs the extra few kilos you might lose with tirzepatide.
Side Effects and Your Stomach
Both medications cause similar side effects. Because they slow down your digestion, you are likely to experience some stomach issues, especially when you first start or when you increase your dose.
The most common complaints are nausea, diarrhea, constipation, and vomiting.
You might assume that because tirzepatide is stronger, it causes worse side effects. Surprisingly, the opposite seems to be true. In the head-to-head SURMOUNT-5 trial, only 2.7% of people on tirzepatide stopped taking the medication because of stomach issues. For semaglutide, the dropout rate was more than double, at 5.6% [surmount5_nejm_2025].
Medical researchers believe the GIP hormone in tirzepatide actually helps calm the nausea caused by the GLP-1 hormone [knop_dom_2024]. It acts like a built-in buffer.
Living in Kuwait adds a specific challenge to these side effects. During the long, intense summer months, dehydration is a real risk. If you are experiencing nausea from either medication, you might not feel like drinking water. You have to force yourself to sip fluids throughout the day.
Ramadan also requires careful planning. Fasting for 14 hours while on a medication that suppresses your appetite and slows your digestion means you need to be very strategic about your Iftar and Suhoor meals. Many doctors in Kuwait recommend taking your weekly injection a day or two before the weekend during Ramadan, so if you feel nauseous, you are at home rather than at work.
The New Contender: Wegovy HD (7.2 mg)
The makers of semaglutide (Novo Nordisk) did not ignore tirzepatide's weight loss advantage. Their response is a much higher dose of semaglutide called Wegovy HD.
Standard Wegovy maxes out at 2.4 mg per week. The new high-dose version triples that to 7.2 mg.
In a recent study called the STEP UP trial, researchers tested this 7.2 mg dose on over 1,400 people for 72 weeks. The results closed the gap significantly. People who stuck to the 7.2 mg dose lost 20.7% of their body weight [step_up_lancet_2025]. That puts high-dose semaglutide right in the same neighborhood as maximum-dose tirzepatide.
Higher-dose semaglutide programs add another layer to this decision. If standard semaglutide is not giving you the result you want, future higher-dose options may matter, but Kuwait pharmacy availability may arrive later than headline regulatory news.
What Happens When You Stop?
This is the reality of modern obesity medicine: these are chronic treatments. They are not quick fixes.
We know exactly what happens when you stop taking them because researchers tested it. In the SURMOUNT-4 trial, patients took tirzepatide for 36 weeks and lost about 21% of their weight. Then, half the group was secretly switched to a placebo (a dummy pen with no medicine).
Over the next year, the people who stayed on tirzepatide lost even more weight. The people who were switched to the placebo regained 14% of their body weight [surmount4_jama_2024]. In fact, 82.5% of the people who stopped the medication regained at least a quarter of the weight they had lost.
Your brain and your gut go back to their old habits once the medication leaves your system. Your appetite returns, and you stop feeling full after small meals. Whether you choose semaglutide or tirzepatide, you should plan to be on a maintenance dose long-term to keep the weight off.
Cost and Availability in Kuwait
Both medications are available in major Kuwait pharmacy chains like Royal, Ali Abdulwahab, and Boots.
Historically, these medications were very expensive. However, the Kuwait Ministry of Health recently stepped in to regulate the market, mandating price cuts of 30% to 37% across the board.
For Wegovy specifically, the starting doses (0.25 mg, 0.5 mg, 1.0 mg) cost 39.480 KWD per month, the 1.7 mg dose costs 67.110 KWD, and the 2.4 mg maintenance dose costs 94.750 KWD per month. That works out to roughly 1,137 KWD per year at the maintenance dose. Mounjaro pricing varies by dose as well. Spirit Pharmacy in Kuwait offers interest-free installment plans through Tabby, Taly, and Deema (4 payments, no interest), which helps spread the cost. Insurance coverage in Kuwait varies wildly. Some premium private health insurance plans will cover these injections if you have a high BMI and a related health condition like prediabetes or high blood pressure. Most standard plans will not cover them if they are prescribed purely for cosmetic weight loss.
Common Questions
Can I switch from semaglutide to tirzepatide? Yes, many people do. If you hit a weight loss plateau on semaglutide, your doctor might transition you to tirzepatide. You usually won't start at the absolute lowest dose of tirzepatide if your body is already used to a GLP-1 medication, but your doctor will map out a specific dosing schedule to keep your stomach from getting upset.
Which one is better if I have type 2 diabetes? Both are excellent, but tirzepatide generally lowers A1C (average blood sugar) slightly more than semaglutide. In the SURMOUNT-2 trial, nearly half of the patients with diabetes who took tirzepatide achieved normal blood sugar levels [surmount2_lancet_2023]. However, weight loss is always slower for people with diabetes compared to people without it, regardless of which pen you use.
Do I need to follow a diet while taking these? Absolutely. These injections make dieting easier by turning down the "food noise" in your brain, but they do not magically burn fat if you eat poorly. In the SURMOUNT-3 trial, people who did an intensive diet and exercise program before starting tirzepatide lost a massive 26.6% of their total body weight [surmount3_nature_2023]. High protein intake is especially important to make sure you are losing fat, not muscle.
Are they safe to use during Kuwait's summer? Yes, but you must manage your hydration. Both medications can blunt your natural thirst mechanism. When it is 45°C outside in Kuwait, you cannot rely on feeling thirsty to remind you to drink. You need to actively track your water intake to avoid kidney strain.
Related Pages * Wegovy vs Mounjaro: Brand Comparison * Best Weight Loss Injection in Kuwait
*
This article is based on the Kuwait HA-approved Wegovy leaflet (revised September 2024) and published clinical evidence. It does not replace advice from your doctor.